Loading…
← CockpitCompetitor Analysis › 301393.SZ Suzhou Highfine Biotech Co., Ltd. Class AOpen in the cockpit ↗

Suzhou Highfine Biotech Co., Ltd. Class A301393.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Major Diversified

Suzhou-based biotech/fine-chemicals company; specific product line not established from available knowledge.

Momentum weak 33
Mkt cap
$786M
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$19.8M
20-day average traded
Fwd P/E
29.4×
forward earnings
ROIC−WACC
-2.5 pp
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
148 days
15 Apr 2027
Close · CNYCN¥49.47
1D-4.9%
1W-10.1%
1M-19.1%
3M-28.4%
6M-15.0%
YTD-2.4%
1Y-8.2%
ATR %6.2%
52w lowhigh33.8% off high

What Suzhou Highfine Biotech does

Suzhou-based biotech/fine-chemicals company; specific product line not established from available knowledge.

Where it sits in the supply chain

  • Materials

Moat: none

Headquarters: Suzhou, China · Employees: 678

Suzhou Highfine Biotech at a glance

Size Suzhou Highfine Biotech (301393.SZ) is a China Materials company (Chemicals: Major Diversified) with a market value of $786M, the 2626th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥49.47 on 18 Nov 2026.

Performance Over six months the shares fell 15.0%, against -23.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 35.6% over the last twelve months (peer median +8.4%); the operating margin is 17.4% (peer median 10.4%).

Valuation It trades at 29.4× forward earnings against a peer median of 19.5× (5th most expensive of 15).

Capital Return on invested capital runs 2.5 points below its cost of capital (10.5% WACC).

Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026301393.SZ 79Peer median 77
Six months, rebased to 100: Suzhou Highfine Biotech against the median of its 20 peers (local-currency closes).

Suzhou Highfine Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥757MCN¥600MCN¥451MCN¥388MCN¥445M
Revenue growth—+33%+16%-13%—
Gross profitCN¥268MCN¥194MCN¥173MCN¥144MCN¥189M
EBITDAn/aCN¥143MCN¥114MCN¥92.2MCN¥154M
Net incomeCN¥123MCN¥115MCN¥134MCN¥99.0MCN¥129M
Free cash flow-CN¥373M-CN¥108MCN¥29.6M-CN¥31.1MCN¥59.1M
Capital expenditureCN¥436MCN¥211MCN¥108MCN¥120MCN¥81.4M
Total debtCN¥146MCN¥115MCN¥17.2MCN¥13.8MCN¥28.0M

Quarterly statements and history in the cockpit →

Suzhou Highfine Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%4471603155497568835941896053665234300121688237603181300530300641300082002274RPEL000635301206603360214370JUBLINGREA301393.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Suzhou Highfine Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×4471603155497541896053665234688237300082002274603360JUBLINGREA301393.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Suzhou Highfine Biotech is the large dot.

Suzhou Highfine Biotech competitors and peer comparison

How Suzhou Highfine Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Suzhou Highfine Biotech against its 20 peers (data as of 18 Nov 2026)
Measure301393.SZPeer medianRank in peer set
1-month return-19.1%-12.0%5th lowest of 21
6-month return-15.0%-23.1%8th highest of 21
Distance from 52-week high-33.8%-39.3%10th highest of 21
Revenue growth (TTM)+35.6%+8.4%2nd highest of 21
Operating margin17.4%10.4%5th highest of 21
Forward P/E29.4×19.5×5th most expensive of 15
ROIC minus cost of capital-2.5 pp-1.0 pp10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Suzhou Highfine Biotech 301393.SZChina$786M-15%+36%17%29.4×n/an/a
Sanyo Chemical Industries 4471.TJapan$794M+8%+8%11%9.6×-7.2%-2.5%
Xinyaqiang Silicon Chemistry 603155.SSChina$798M-15%+25%12%37.4×22.5%+3.9%
JCU 4975.TJapan$744M-34%+5%39%13.4×5.5%+7.0%
Guangzhou Sanfu Newmaterials Technology 688359.SSChina$832M-54%+8%-7%n/an/an/a
KH Neochem 4189.TJapan$738M+20%-6%12%11.8×-5.0%+8.3%
Jiangxi Hungpai New Material 605366.SSChina$736M-46%+9%-11%211.7×n/an/a
Daxin Materials 5234.TWTaiwan$705M-39%+12%20%15.8×15.9%+1.5%
Shandong Yanggu Huatai Chemical 300121.SZChina$703M-16%+11%8%17.5×4.7%+12.1%
Hubei Chaozhuo Aviation Technology 688237.SSChina$697M-5%-1%1%37.3×43.1%+26.0%
Zhejiang Huangma Technology 603181.SSChina$891M-33%+7%17%13.8×n/an/a
Hunan Lead Power Technology 300530.SZChina$691M+12%+16%-61%n/an/an/a
Jiangsu Zhengdan Chemical Industry 300641.SZChina$914M-29%-30%17%n/a7.1%+11.6%
Liaoning Oxiranchem,Inc 300082.SZChina$673M-45%+4%0%33.0×n/an/a
Jiansu Huachang Chemical 002274.SZChina$663M-25%+9%-3%5.6×23.2%+1.3%
Raghav Productivity Enhancers RPEL.NSIndia$942M+109%+38%28%n/an/an/a
Ningxia Yinglite Chemicals 000635.SZChina$650M+35%-14%-48%n/an/an/a
Shandong Sanyuan Biotechnology 301206.SZChina$644M-21%+15%4%n/an/an/a
Dalian Bio-Chem 603360.SSChina$971M-54%0%16%21.7×8.5%+18.4%
Caregen 214370.KSSouth Korea$982M-74%-2%20%21.5×36.8%+3.8%
Jubilant Ingrevia JUBLINGREA.NSIndia$1.00B-19%+15%10%21.6×28.0%+44.9%

Questions

Which companies are Suzhou Highfine Biotech's closest peers?
The cockpit's peer set: Sanyo Chemical Industries (4471.T), Xinyaqiang Silicon Chemistry (603155.SS), JCU (4975.T), Guangzhou Sanfu Newmaterials Technology (688359.SS), KH Neochem (4189.T), Jiangxi Hungpai New Material (605366.SS), Daxin Materials (5234.TW), Shandong Yanggu Huatai Chemical (300121.SZ).
Is Suzhou Highfine Biotech expensive compared with its peers?
On forward p/e it trades at 29.4× against a peer median of 19.5×, 5th most expensive of 15 in its peer set.
How has Suzhou Highfine Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -15.0% against -23.1% for the median peer; over one year -8.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.